ABT 737-d8

ABT 737-d8 is a deuterium-labeled version of the small molecule ABT 737, a potent inhibitor of B-cell lymphoma 2 (Bcl-2) family proteins. Bcl-2 family proteins are involved in regulating programmed cell death, or apoptosis, and are frequently overexpressed in cancer cells, allowing them to evade apoptosis and continue proliferating. ABT 737-d8 is a valuable tool for studying the pharmacokinetics and pharmacodynamics of ABT 737, as the deuterium label allows for more precise measurement of drug concentrations and metabolic pathways in vivo. ABT 737-d8 is typically used in preclinical studies to investigate the efficacy of ABT 737 and other Bcl-2 inhibitors in various cancer models. It has been shown to induce apoptosis in a variety of cancer cell lines, including those from leukemia, lymphoma, and solid tumors. Additionally, ABT 737-d8 has been used in combination with other chemotherapeutic agents to enhance their anti-tumor activity. From a chemical standpoint, ABT 737-d8 is a small molecule with a molecular weight of 882.91 g/mol. It contains eight deuterium atoms, which replace hydrogen atoms in the original ABT 737 molecule. The deuterium labeling increases the mass of the molecule, allowing for more accurate measurement of drug concentrations in biological samples. ABT 737-d8 is typically administered via intravenous injection or oral gavage in preclinical studies.